Combination MEK and mTOR inhibitor therapy is active in models of glioblastoma.

Karisa C SchreckAmy N AllenJiawan Wang Christine A Pratilas

Published in: Neuro-oncology advances (2020)

These data demonstrate that combined MEK/mTOR inhibition is synergistic in glioblastoma cell lines and may be more potent in NF1-deficient glioblastoma.

Keyphrases

pi k akt
cell proliferation
lps induced
big data
stem cells
mesenchymal stem cells
nuclear factor
inflammatory response